Treat-to-target in spondyloarthritis: implications for clinical trial designs.

doi:10.1007/s40265-014-0246-0

中山醫學大學機構典藏 CSMUIR > 醫學院 > 醫學研究所 > 期刊論文 > Item 310902500/17706

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/17706

题名:	Treat-to-target in spondyloarthritis: implications for clinical trial designs.
作者:	JC, Wei
贡献者:	醫學研究所
日期:	2014-07
上传时间:	2017-05-31T09:04:01Z (UTC)
ISSN:	0012-6667
摘要:	Spondyloarthritis (SpA) is a chronic inflammatory disease involving the spine and peripheral joints, and extra-articular manifestations such as uveitis, psoriasis and bowel inflammation. The treatment goals for SpA are maintenance of physical function, control of disease activity and prevention of radiographic progression. However, unlike the well-established treat-to-target (T2T) guidance in rheumatoid arthritis, the T2T concept for treating SpA is still immature. Clinical evidence of T2T in SpA is still lacking. To develop evidence of T2T in SpA, several research agendas need to be accomplished. Firstly, a well-accepted measureable treatment target needs to be defined through expert consensus. Secondly, a T2T treatment algorithm for monitoring disease activity and adjusting therapies needs to be generated. Finally, well-designed comparative clinical trials to compare this T2T strategy with the current standard of treatment should be conducted to demonstrate long-term benefits and risks. In SpA clinical trials, T2T comparative studies should have a clear disease definition for enrollment of patients with ankylosing spondylitis (AS), psoriatic arthritis, axial SpA or non-radiographic axial SpA. Endpoints should be assessment with AS International Working Group criteria for 20% improvement (ASAS20), ASAS40, and the Ankylosing Spondylitis Disease Activity Score (ASDAS) with inactive and moderate disease activity at month 3. Long-term efficacy endpoints such as the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) of radiographic progression and magnetic resonance imaging (MRI) score at 2 years are encouraged. More sensitive assessment tools to detect structural damage and new bone formation, such as low-radiation computerized tomography (CT), are promising.
URI:	http://dx.doi.org/10.1007/s40265-014-0246-0 https://ir.csmu.edu.tw:8080/ir/handle/310902500/17706
關聯:	Drugs. 2014 Jul;74(10):1091-6.
显示于类别:	[醫學研究所] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	162	检视/开启

检视Licence

在CSMUIR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....